Dementias pp 233-251 | Cite as

Pharmacotherapeutic Approach to the Treatment of Alzheimer Disease

  • E. Giacobini


A systematic attempt to develop drugs to treat Alzheimer disease (AD) was initiated on a large scale 10 years ago following publication in the New England Journal of Medicine of the first successful results obtained with the Cholinesterase inhibitor (ChEI) tacrine (THA, tetrahydroaminoacridine) by Summers et al. [1]. Tacrine is not the first ChEI to be tested clinically for treating AD. Numerous studies [2] had been performed previously, particularly in the USA, in small groups of patients, with physostigmine (physo) alone or in combination with lecithin. Physostigmine, like tacrine, showed definite but only short-lasting improvements in cognitive symptoms (attention, concentration, memory), which were accompanied with severe peripheral and central cholinergic side effects. These consisted mainly of gastrointestinal symptoms and drowsiness, but in the case of tacrine also of liver toxicity. It was soon realized that in spite of this first encouraging result, both physo and tacrine were far from an ideal drug for AD treatment. However, physo and tacrine represent important milestones in AD therapy, as they supported for the first time in the patient the pharmacological hypothesis formulated in the experimental animal [3, 4, 5, 6] that a treatment improving function of the central cholinergic system obtained through an increase in brain acetylcholine (ACh) would also improve cognition in AD patients. Targeting the cholinergic system for AD therapy does not necessarily limit itself to use of a ChEI. Two other classes of cholinergic drugs might represent valid alternatives, such as nicotinic and muscarinic agonists alone or in combination with ChEI (Fig. 1).


Alzheimer Disease Cholinesterase Inhibitor Alzheimer Disease Patient Muscarinic Agonist Amyloid Precursor Protein Processing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Summers WK, Majovski LV, Marsh GM, Tachiki K, Kling A (1986) Oral tetrahydroaminoacridine in long term treatment of senil dementia, Alzheimer type. N Engl J Med 315: 1241–1245PubMedCrossRefGoogle Scholar
  2. 2.
    Becker R, Moriearty P, Unni L (1991) The second generation of Cholinesterase inhibitors: clinical and pharmacological effects. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 263–296Google Scholar
  3. 3.
    Mattio T, Mcllhany M, Giacobini E, Hallak M (1986) The effects of physostigmine on acetylcholinesterase activity of CSF, plasma and brain. A comparison of intravenous and intraventricular administration in beagle dogs. Neuropharmacology 25: 1167–1177PubMedCrossRefGoogle Scholar
  4. 4.
    Giacobini E (1987) Models and strategies of cholinomimetic therapy of Alzheimer disease. In: Dowdall MJ, Hawthorne JN (eds) Cellular and molecular basis of cholinergic function. Horwood, New York, pp 882–901Google Scholar
  5. 5.
    Hallak M, Giacobini E (1986) Relation of brain regional physostigmine concentrations to Cholinesterase activity, and acetylcholine and choline levels in rat. Neurochem Res 11: 1037–1048PubMedCrossRefGoogle Scholar
  6. 6.
    Giacobini E, Mussini I, Mattio T (1986) Aging of cholinergic synapses: fiction or reality. In: Hanin I (ed) Dynamics of cholinergic function, vol 30. Plenum, New York, pp 177–190CrossRefGoogle Scholar
  7. 7.
    Checler F (1995) Processing of the b-amyloid precursor protein and its regulation in Alzheimer’s disease. J Neurochem 65: 1431–1444PubMedCrossRefGoogle Scholar
  8. 8.
    Van Broeckhoven C (1995) Presenilins and Alzheimer disease. Nat Genet 11: 230–232PubMedCrossRefGoogle Scholar
  9. 9.
    Sandbrink R, Hartmann T, Masters CL, Beyreuther K (1996) Genes contribution to Alzheimer’s disease. Mol Psychiatry 1: 27–40PubMedGoogle Scholar
  10. 10.
    Vito P, Lacaná E, D’Adamio L (1996) Interfering with apoptosis: Ca2+-binding protein ALG-2 and Alzheimer’s disease gene ALG-3. Science 271: 521–525PubMedCrossRefGoogle Scholar
  11. 11.
    Roses A (1995) Perspective on the metabolism of apolipoprotein E and the Alzheimer disease. Exp Neurol 132: 149–156PubMedCrossRefGoogle Scholar
  12. 12.
    Giacobini E (1996) Cholinesterase inhibitors do more than inhibit Cholinesterase. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 187–204Google Scholar
  13. 13.
    Yankner B (1996) New clues to Alzheimer’s disease: unraveling the roles of amyloid and tau. Nat Med 2: 850–852PubMedCrossRefGoogle Scholar
  14. 14.
    Soininen H, Riekkinen J Sr (1996) Apolipoprotein E, memory and Alzheimer’s disease. Trends Neursosci 19: 224–228CrossRefGoogle Scholar
  15. 15.
    Haroutunian V, Greig NH, Gluck R, Fiber E, Davis KL, Wallace WC (1995) Selective attenuation of lesion-induced increases in secreted b-APP by acetylcholinesterase inhibitors. Soc Neurosci 21 208.1: 502Google Scholar
  16. 16.
    Haroutunian V, Greig N, Pei XF, Utsuki L, Acevedo LD, Gluck R, Davis KL, Wallace D (1996) Pharmacological modulation of Alzheimer’s b-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions. Soc Neurosci 22 461.7: 1169Google Scholar
  17. 17.
    Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljärvi L, Talasniemi S, Ryynänen M, Riekkinen P (1995) A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein e4 allele. Neurosci Lett 187: 79–82PubMedCrossRefGoogle Scholar
  18. 18.
    Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 92: 12260–12264PubMedCrossRefGoogle Scholar
  19. 19.
    Nordberg A (1993) Clinical studies in Alzheimer patients with positron emission tomography. Behav Brain Res 57: 215–224PubMedCrossRefGoogle Scholar
  20. 20.
    Nordberg A (1995) Long term treatment effects on progression of Alzheimer’s disease as determined by functional brain studies. In: Ikbal K, Mortimer JA, Winblad B, Wiesniewski HM (eds) Research advances in alzheimer’s disease and related disorders. Wiley, Chichester, pp 293–298Google Scholar
  21. 21.
    Gracon S, Smith F, Hoover T (1996) Long-term tacrine treatment: effect on nursing home placement and mortality. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 205–209Google Scholar
  22. 22.
    Ogane N, Giacobini E, Struble R (1992) Differential inhibition of acetylcholinsterase molecular forms in normal and Alzheimer disease brain. Brain Res 589: 307–312PubMedCrossRefGoogle Scholar
  23. 23.
    Anand R, Hartman RD, Hayes PE (1996) An overview of the development of SDZ ENA 713, a brain selective Cholinesterase inhibitor. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 239–243Google Scholar
  24. 24.
    Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowski CH, Dolan-Ureno JA (1992) Controlled trial of tacrine in Alzheimer’s disease. J Am Med Assoc 268: 2523–2529CrossRefGoogle Scholar
  25. 25.
    Knapp ZJ, Knopman DS, Solomon PR (1994) A 30 week randomized controlled trial of high-dose tacrine in patients with Alzheimer’s disease. JAMA 271: 985–991PubMedCrossRefGoogle Scholar
  26. 26.
    Roger SL, Friedhoff T (1996) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebocontrolled trial. Dementia 7: 293–303Google Scholar
  27. 27.
    Becker R, Moriearty P, Unni L, Vicari S (1996) Cholinesterase inhibitors as therapy in Alzheimer’s disease: benefit to risk considerations in clinical application. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 257–266Google Scholar
  28. 28.
    Giacobini E, Becker R, Mcllhany M, Kumar V (1988) Interacerebroventricular administration of cholinergic drugs: preclinical trials and clinical experience in Alzheimer patients. In: Giacobini E, Becker R (eds) Current research in Alzheimer therapy. Taylor and Francis, New York, pp 113–122Google Scholar
  29. 29.
    Giacobini E, Mori F, Buznikov A, Becker R (1995) Cholinesterase inhibitors alter APP secretion and APP mRNA in rat cerebral cortex. Soc Neurosci Abstr 21: 988Google Scholar
  30. 30.
    Giacobini E, DeSarno P, Clark B, Mcllhany M (1989) The cholinergic receptor system of the human brain — neurochemical and pharmacological aspects in aging and Alzheimer. In: Nordberg A, Fuxe K, Holmstedt B (eds) Progress in brain research. Elsevier, Amsterdam, pp 335–343Google Scholar
  31. 31.
    Giacobini E, Cuadra G (1994) Second and third generation Cholinesterase inhibitors: from preclinical studies to clinical efficacy. In: Giacobini E, Becker R (eds) Alzheimer disease: therapeutic strategies. Birkhäuser, Boston, pp 155–171Google Scholar
  32. 32.
    Giacobini E (1994) Cholinomimetic therapy of Alzheimer disease: does it slow down deterioration? In: Racagni G, Brunello N, Langer SZ (eds) Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction, vol 7(23). Internatonal Academy of Biomedical Drug Research. Karger, New York, pp 51–57Google Scholar
  33. 33.
    Giacobini E (1995) Cholinesterase inhibitors: from preclinical studies to clinical efficacy in Alzheimer disease. In: Quinn D, Balasubramaniam AS, Doctor BP, Taylor P (eds) Enzymes of the Cholinesterase family. Plenum, New York, pp 463–469Google Scholar
  34. 34.
    Rupniak NMJ, Field MJ, Samson NA, Steventon MJ, Iversen SD (1990) Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol Aging 11: 609–613PubMedCrossRefGoogle Scholar
  35. 35.
    Messamore E, Warpman U, Williams E, Giacobini E (1993) Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after Cholinesterase inhibition. Neurosci Lett 158: 205–208PubMedCrossRefGoogle Scholar
  36. 36.
    Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Master CL, Grzeschil KH, Multaup G, Beyreuther K, Muller-Hill B (1987) The precursor of Alzheimer disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733–736PubMedCrossRefGoogle Scholar
  37. 37.
    Beeson JG, Shelton ER, Chan HW, Gage FH (1994) Differential distribution of amyloid protein precursor immunoreactivity in the rat brain studied by using five different antibodies. J Comp Neurol 342: 78–96PubMedCrossRefGoogle Scholar
  38. 38.
    Sisodia SS, Koo EH, Beyreuther K, Unterbeck A, Price DL (1990) Evidence that beta amyloid protein in Alzheimer disease is not derived by normal processing. Science 248: 492–495PubMedCrossRefGoogle Scholar
  39. 39.
    Nitsch RM, Slack BE, Wurtman RJ, Growdon JH (1992) Release of Alzheimer precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258: 304–307PubMedCrossRefGoogle Scholar
  40. 40.
    Buxbaum JD, Oishi M, Chen HI, Pinkas-Kramarski R, Jaffe EA, Gandy SE, Greengard P (1992) Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer βA4 amyloid protein precursor. Proc Natl Acad Sci USA 89: 10075–10078PubMedCrossRefGoogle Scholar
  41. 41.
    Buxbaum JD (1995) Post-translational control of the amyloid b-protein precursor processing. In: Nitsch RM, Growdon JM (eds) Pathobiology of Alzheimer’s disease. Academic, New York, pp 98–114Google Scholar
  42. 42.
    Nitsch RM, Growdon JH (1994) Role of neurotransmission in the regulation of amyloid beta-protein precursor processing. Biochem Pharmacol 47: 1275–1284PubMedCrossRefGoogle Scholar
  43. 43.
    Lahiri DK, Lewis S, Farlow MR (1994) Tacrine alters the secretion of the beta-amyloid precursor protein in cell lines. J Neurosci Res 37: 777–787PubMedCrossRefGoogle Scholar
  44. 44.
    Chong YH, Suh YH (1996) Amyloidogenic processing of Alzheimer’s amyloid precursor protein in vitro and its modulation by metal ions and tacrine. Life Sci 59: 545–557PubMedCrossRefGoogle Scholar
  45. 45.
    Mori F, Lai CC, Fusi F, Giacobini E (1995) Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuroreport 6: 633–636PubMedCrossRefGoogle Scholar
  46. 46.
    Nitsch RM, Farber SA, Growdon JH, Wurtman RJ (1993) Release of amyloid beta-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc Natl Acad Sci USA 90: 191–193Google Scholar
  47. 47.
    Anderson JP, Refolo LM, Wallace W, Mehta P, Krishnamurthi M, Gotlib J, Bierer L, Haroutunian V, Perl D, Robakis NK (1989) Differential brain expression of the Alzheimer’s amyloid precursor protein. EMBO J 8: 3627–3632PubMedGoogle Scholar
  48. 48.
    Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva O, Soto C, Garrido J (1996) AChE accelerates assembly of amyloid-b peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme. Neuron 16: 881–891PubMedCrossRefGoogle Scholar
  49. 49.
    Small DH, Moir RD, Fuller SJ, Michaelson S, Bush A, Qiao-Xin L, Milward E, Hilbich C, Weidemann A, Beyreuther K, Colin Masters L (1991) A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer’s disease. Biochemistry 30: 10795–10799PubMedCrossRefGoogle Scholar
  50. 50.
    Funes S (1996) Acétylcholinestérase et maladie d’Alzheimer. Thèse présentée pour obtenir le grade de docteur de l’Université de Louis Pasteur, StrasbourgGoogle Scholar
  51. 51.
    Chong YH, Jung JM, Choi W, Park CW, Sou Choi K, Suh YH (1994) Bacterial expression, purification of full length and carboxyl terminal fragment of Alzheimer amyloid precursor protein and their proteolytic processing by thrombin. Life Sci 54: 1259–1268PubMedCrossRefGoogle Scholar
  52. 52.
    Wallace WC, Bragin V, Robakis NK, Sambamurti K, VanderPutten D, Merril CR, Davis KL, Santucci AC, Haroutunian V (1991) Increased biosynthesis of Alzheimer amyloid precursor protein in the cerebral cortex of rats with lesions of the nucleus basalis of Meynert. Mol Brain Res 10: 173–178PubMedCrossRefGoogle Scholar
  53. 53.
    Nordberg A (1996) Pet imaging of nicotinic receptors in Alzheimer’s disease — implication with diagnosis and drug treatment. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 439–444Google Scholar
  54. 54.
    Minthon L, Nilsson K, Edvinsson L, Wendt PE, Gustafson L (1995) Long-term effects of tacrine on regional cerebral blood flow changes in Alzheimer’s disease. Dementia 6: 245–251PubMedGoogle Scholar
  55. 55.
    Perry EK, Perry RH, Blessed G, Tomlinson BE (1978) Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol 4: 273–277PubMedCrossRefGoogle Scholar
  56. 56.
    Davies P (1979) Neurotransmitter-related enzymes in senile dementia of the Alzheimer Type. Brain Res 171: 319–327PubMedCrossRefGoogle Scholar
  57. 57.
    Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH (1987) Molecular forms of butyrylcholinesterase in the human neocortex during development and degeneration of the cortical cholinergic system. J Neurochem 48: 1687–1692PubMedCrossRefGoogle Scholar
  58. 58.
    Arendt T, Brückner M, Lange M, Bigl V (1992) Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development — a study of molecular forms. J Neurochem 21: 381–396CrossRefGoogle Scholar
  59. 59.
    Canal I, Imbimbo BP (1996) Clinical trials and therapeutics: relationship between pharmacodynamic activity and cognitive effects of eptastigmine in patiens with Alzheimer’s disease. Clin Pharmacol Ther 60: 1–11CrossRefGoogle Scholar
  60. 60.
    Imbimbo BP (1996) Eptastigmine: a cholinergic approach to the treatment of Alzheimer’s disease. In: Becker R, Giacobini E (eds) Alzheimer disease: from molecular biology to therapy. Birkhäuser, Boston, pp 223–230Google Scholar
  61. 61.
    Thal L, Fuld PA, Masur DM, Sharpless NS (1983) Oral physostigmine and lecithin improve memory in Alzheimer disease. Ann Neurol 13: 491–496PubMedCrossRefGoogle Scholar
  62. 62.
    Imbimbo BP, Lucchelli PE (1994) A pharmacodynamic strategy to optimize the clinical response to eptastigmine (MF-201). In: Giacobini E, Becker R (eds) Alzheimer disease: therapeutic strategies. Birkhäuser, Boston pp 103–107Google Scholar
  63. 63.
    Becker R, Colliver J, Elble R (1990) Effects of metrifonate, a long-acting Cholinesterase inhibitor, Alzheimer disease: report of an open trial. Drug Dev Res 19: 425–434CrossRefGoogle Scholar
  64. 64.
    Knapp S, Wardlow ML, Albert W, Waters D, Thal J (1991) Correlation between plasma physostigmine concentrations and percentage of acetylcholinesterase inhibition over time after controlled release of physostigmine in volunteer subjects. Drug Metab Dispos 19: 400–404PubMedGoogle Scholar
  65. 65.
    Giacobini E, Zhu XD, Williams E, Sherman KA (1996) The effect of the selective reversible acethylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amines levels in rat cortex. Neuropharmacology 35: 205–211PubMedCrossRefGoogle Scholar
  66. 66.
    Zuh XD, Cuadra G, Brufani M, Maggi T, Pagella PG, Williams E, Giacobini E (1996) Effects of MF268, a new Cholinesterase inhibitor, on acetylcholine and biogenic amines in rat cortex. J Neurosci Res 43: 120–126CrossRefGoogle Scholar
  67. 67.
    Mori F, Cuadra G, Giacobini E (1995) Metrifonate effects on acetylcholine and biogenic amines in rat cortex. Neurochem Res 20: 1081–1088PubMedCrossRefGoogle Scholar
  68. 68.
    Zhu XD, Giacobini E, Hornsperger JM (1995) Effect of MDL 73,745 on acetylcholine and biogenicamine levels in rat cortex. Eur J Pharmacol 276: 93–99PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1999

Authors and Affiliations

  • E. Giacobini

There are no affiliations available

Personalised recommendations